Wednesday, December 14, 2022
Rapid Therapeutics Science Laboratories, a growth-oriented aerosol manufacturing company focused on natural relief innovations through trusted aerosol delivery, announces today that it has moved three (3) proprietary pharmaceutical grade patents from provisional to non-provisional status.
Donal R. Schmidt, Jr. CEO states: “All three patent applications are specially designed for inhalation of CBD and CBG with the expectation they will eventually be approved by the FDA for delivery in a pressurized metered dose inhaler (pMDI).” RTSL previously marketed both CBD and CBG delivered in MDI through pharmacies and physicians before removing them from the public market to focus on research and FDA approval of its inhaled products.
RTSL expects to announce additional patent applications of pharmaceutical grade cannabinoids in the next few weeks; including but not limited to, blends and THC based inhalants which are in the research only phase.
